The company's coagulation device uses a proprietary biochip platform to monitor platelet function tests, clotting times, and viscoelasticity, enabling the monitoring of specific drugs or blood products. Additionally, Atantares offers a chimeric antigen receptor that aids in the treatment of hematological tumors, cardiac diseases, neurological disorders, and cancer. This receptor utilizes an ultrasensitive immunoassay platform to provide cytokine profile data for managing CAR T-cell therapy and CRS mitigation. By combining biochip and AI technologies, Atantares is driving the next generation of precision medicine in hematology, cardiology, neurology, and cancer. The company is headquartered in Cambridge, Massachusetts.